# Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis

> **NCT05344482** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 277 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **OTHER:** Secukinumab

## Key facts

- **NCT ID:** NCT05344482
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-09
- **Primary completion:** 2021-08-31
- **Final completion:** 2021-08-31
- **Target enrollment:** 277 (ACTUAL)
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05344482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05344482, "Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05344482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*